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Background
B cells play a crucial role in the pathogenesis of rheu-
matoid arthritis (RA). They are responsible for the auto-
antibodies formation such as rheumatoid factor (RF)
and anti- cyclic citrullinated peptide antibodies (anti-
CCP) and the production of cytokines, act as antigen
presenting cells and regulate T cell functions.
Rituximab (RTX), murine monoclonal antibody which
selectively targets CD20-positive B-cells, has proved to
be an efective and safe therapy for active RA. Initially it
was used in seropositive RA, but considering the other
functions of B cells, it is logical to think that it is also
useful in seronegative forms.
Objective
To evaluate the efficacy of RTX in our series of refrac-
tory seronegative and seropositive RA.
Materials and methods
Baseline characteristics and disease activity markers at
baseline, and after 3 and 6 months of treatment with
RTX (1 g x 2 weeks), were collected in 33 patients. A
descriptive study was made; and the relations between
variables were analyzed statistically.
Results
The mean age was 52.06 ± 12.01 years, 75.8% female,
78.8% RF positive (26). The mean duration of illness
was 7.70 ± 4.47 years. Thirty-two patientes (97%) had
failed at least to one TNF antagonist.
Most of the patients (84.8% 9) received RTX with
methotrexate.
The mean DAS28 at baseline was 5.7 ± 1.30; at 3
months decreased to 3.4 ± 1.22, and at 6 months to
4.15 ± 1.69 ( p < 0.0005).
At 3 months, 88.9% reached good eular response, and
63.3% at 6 months. Remission was obtained in 17.2% at
3 months and in 16.7% at 6 months.
It was also noted improvement in baseline HAQ, after
3 and 6 months (from 1.75 ± 0.767 to 0.96 ± 0.56 and
1.24 ± 0.70 respectively).
No significant differences were found between decreases
in DAS 28 at 3 and 6 months compared to baseline
between RF seronegative and seropositive patients, neither
in good eular response, remission percentages or HAQ
improvement. The data are shown in the table.
Discussion
The efficacy and safety of RTX has been proved in
several clinical trials.
The presence of RF, low baseline functional disability
and no more than one previous anti-TNF are predictors
of good response to RTX, as has been recently published.
Response rates in seronegative RA, are slightly lower,




























RF + 5.73 ± 1.24 3.38 ± 1.30 4.13 ± 1.83 90.5% 65.2% 18.2% 17.4% 1.81 ± 0.77 1.00 ± 0.57 1.2 ± 0.74
RF - 5.52 ± 1.61 3.72 ± 0.93 4.22 ± 1.23 83.3% 57.1% 14.3% 14.3% 1.57 ± 0.78 0.83 ± 0.56 0.95 ± 0.54
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In conclussion, the experience of RTX treatment in our
patients with seronegative RA is positive, in terms of effi-
cacy, due to the action on B cells and their different roles,
with no significant differences comparing to seropositive
RA.
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